Posted at 18:54h
by aveak
...Aptevo Therapeutics makes no express or implied representations or warranties regarding the usability or condition of this website, that this website will operate uninterrupted or error-free, or that this website...
Posted at 17:55h
by aveak
...how we use, disclose, and protect the information that we collect about you when you: Visit our website (http://aptevotherapeutics.com) and any other websites that link to this Policy (collectively, the...
Posted at 15:42h
by aveak
...Signs of clinical activity – both stable disease and complete remissions, were also observed. View results from our presentation at ASH 2021 https://aptevotherapeutics.gcs-web.com/static-files/638ab153-b1ff-49ee-b4b3-b1bed667bf73 View All Mipletamig Scientific Presentations Here: https://aptevotherapeutics.gcs-web.com/presentations...
Posted at 17:19h
by aveak
APVO442 (PSMA x CD3): Multi Specific Candidate for the Treatment of Prostate Cancer A Preclinical Program Utilizing ADAPTIR-FLEX to Target PSMA with High Affinity, and to CD3 with Low Affinity,...
Posted at 16:21h
by aveak
...is a multi-center, multi-cohort, open-label trial that will include six dose levels. Patients will be assigned to dose levels according to a 3+3 design paradigm. The trial will be conducted...
Posted at 01:12h
by aveak
Contact Us Aptevo Therapeutics – Headquarters 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Tel: 206-838-0500 Fax: 206-838-0503 info@apvo.com Investor Relations & Corporate Communications Miriam Weber Miller Tel: 206-859-6628 Millerm@apvo.com...
Posted at 13:37h
by aveak
...compensation and benefits, performance management, learning and development. She brings more than 25 years of experience across industries including insurance, high-tech and biologics, gene and cell therapy, advising executives and...
Posted at 18:52h
by aveak
...Action ADAPTIR – Modular Bispecific Platform Technology Supports Development of Novel Therapeutics ADAPTIR Bispecifics are based on a robust technology platform with potential advantages over other platforms including; Increased stability...
Posted at 16:42h
by aveak
...as a dual agonist bispecific antibody APVO603 has the potential to produce a synergistic or amplified response resulting in more robust T cell response View APVO603 Scientific Presentations Here: https://aptevotherapeutics.gcs-web.com/presentations...
